Proqr Therapeutics Bv Stock Analysis
| PRQR Stock | USD 3.84 0.17 4.63% |
ProQR Therapeutics BV is fairly valued with Real Value of 3.95 and Target Price of 3.93. The main objective of ProQR Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what ProQR Therapeutics BV is worth, separate from its market price. There are two main types of ProQR Therapeutics' stock analysis: fundamental analysis and technical analysis.
The ProQR Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. ProQR Therapeutics is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. ProQR Stock trading window is adjusted to America/New York timezone.
ProQR |
ProQR Stock Analysis Notes
About 14.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.32. ProQR Therapeutics had not issued any dividends in recent years. ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands. Proqr Therapeutics is traded on NASDAQ Exchange in the United States. To find out more about ProQR Therapeutics BV contact Daniel Boer at 31 88 166 7000 or learn more at https://www.proqr.com.ProQR Therapeutics Investment Alerts
| ProQR Therapeutics is way too risky over 90 days horizon | |
| ProQR Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 6.51 M. Net Loss for the year was (27.54 M) with profit before overhead, payroll, taxes, and interest of 4.8 M. | |
| About 14.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: ProQR Therapeutics Shares Cross Above 50 Day Moving Average - Time to Sell - MarketBeat |
ProQR Therapeutics Upcoming and Recent Events
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 21st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
ProQR Largest EPS Surprises
Earnings surprises can significantly impact ProQR Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-09 | 2024-03-31 | -0.11 | -0.09 | 0.02 | 18 | ||
2023-11-07 | 2023-09-30 | -0.09 | -0.07 | 0.02 | 22 | ||
2022-05-05 | 2022-03-31 | -0.24 | -0.2 | 0.04 | 16 |
ProQR Therapeutics Environmental, Social, and Governance (ESG) Scores
ProQR Therapeutics' ESG score is a quantitative measure that evaluates ProQR Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of ProQR Therapeutics' operations that may have significant financial implications and affect ProQR Therapeutics' stock price as well as guide investors towards more socially responsible investments.
ProQR Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 155.9 K | Franklin Street Advisors Inc. | 2024-09-30 | 150 K | Millennium Management Llc | 2024-06-30 | 148.4 K | Two Sigma Advisers, Llc | 2024-06-30 | 131.5 K | Boothbay Fund Management, Llc | 2024-09-30 | 106.7 K | Susquehanna International Group, Llp | 2024-06-30 | 96.1 K | Citadel Advisors Llc | 2024-09-30 | 87 K | Squarepoint Ops Llc | 2024-06-30 | 84.7 K | Bank Of America Corp | 2024-06-30 | 73.2 K | Privium Fund Management B.v. | 2024-09-30 | 5.6 M | Adage Capital Partners Gp Llc | 2024-06-30 | 3.6 M |
ProQR Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 406.68 M.ProQR Profitablity
The company has Profit Margin (PM) of (1.3) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.19) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.19.| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.20) | (0.21) | |
| Return On Capital Employed | (0.31) | (0.32) | |
| Return On Assets | (0.20) | (0.21) | |
| Return On Equity | (0.68) | (0.65) |
Management Efficiency
ProQR Therapeutics has return on total asset (ROA) of (0.1486) % which means that it has lost $0.1486 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6714) %, meaning that it created substantial loss on money invested by shareholders. ProQR Therapeutics' management efficiency ratios could be used to measure how well ProQR Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 12/01/2024, Return On Tangible Assets is likely to drop to -0.21. In addition to that, Return On Capital Employed is likely to drop to -0.32. At this time, ProQR Therapeutics' Non Current Assets Total are relatively stable compared to the past year. As of 12/01/2024, Other Current Assets is likely to grow to about 1.2 M, while Total Current Assets are likely to drop slightly above 100.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.51 | 0.49 | |
| Tangible Book Value Per Share | 0.51 | 0.49 | |
| Enterprise Value Over EBITDA | (1.91) | (2.00) | |
| Price Book Value Ratio | 3.51 | 3.68 | |
| Enterprise Value Multiple | (1.91) | (2.00) | |
| Price Fair Value | 3.51 | 3.68 | |
| Enterprise Value | 45.9 M | 43.6 M |
At ProQR Therapeutics, management's focus on innovation and efficiency has led to impressive financial results. We assess these factors to determine the stock's attractiveness to investors.
Operating Margin (2.19) | Profit Margin (1.30) | Beta 0.253 | Return On Assets (0.15) | Return On Equity (0.67) |
Technical Drivers
As of the 1st of December, ProQR Therapeutics holds the Coefficient Of Variation of 905.68, risk adjusted performance of 0.0939, and Semi Deviation of 2.31. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of ProQR Therapeutics, as well as the relationship between them. Please check ProQR Therapeutics variance and potential upside to decide if ProQR Therapeutics is priced some-what accurately, providing market reflects its current price of 3.84 per share. Given that ProQR Therapeutics has jensen alpha of 1.3, we recommend you to check out ProQR Therapeutics's recent market performance to make sure the company can sustain itself at a future point.ProQR Therapeutics Price Movement Analysis
The output start index for this execution was nine with a total number of output elements of fifty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. ProQR Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for ProQR Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
ProQR Therapeutics Outstanding Bonds
ProQR Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. ProQR Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ProQR bonds can be classified according to their maturity, which is the date when ProQR Therapeutics BV has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
ProQR Therapeutics Predictive Daily Indicators
ProQR Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of ProQR Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
ProQR Therapeutics Corporate Filings
6K | 7th of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 25th of October 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 24th of October 2024 Other Reports | ViewVerify | |
| 23rd of October 2024 Other Reports | ViewVerify | |
| 10th of October 2024 Other Reports | ViewVerify | |
| 30th of September 2024 Other Reports | ViewVerify | |
6K | 8th of August 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 22nd of May 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
ProQR Therapeutics Forecast Models
ProQR Therapeutics' time-series forecasting models are one of many ProQR Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ProQR Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About ProQR Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how ProQR Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling ProQR shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as ProQR Therapeutics. By using and applying ProQR Stock analysis, traders can create a robust methodology for identifying ProQR entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (4.27) | (4.48) | |
| Operating Profit Margin | (4.89) | (5.14) | |
| Net Loss | (4.32) | (4.53) | |
| Gross Profit Margin | 0.98 | 1.03 |
Current ProQR Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. ProQR analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. ProQR analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 3.93 | Strong Buy | 6 | Odds |
Most ProQR analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand ProQR stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of ProQR Therapeutics, talking to its executives and customers, or listening to ProQR conference calls.
ProQR Stock Analysis Indicators
ProQR Therapeutics BV stock analysis indicators help investors evaluate how ProQR Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading ProQR Therapeutics shares will generate the highest return on investment. By understating and applying ProQR Therapeutics stock analysis, traders can identify ProQR Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 94.8 M | |
| Long Term Debt | 4.3 M | |
| Common Stock Shares Outstanding | 81 M | |
| Total Stockholder Equity | 41.4 M | |
| Tax Provision | -78 K | |
| Property Plant And Equipment Net | 16.9 M | |
| Cash And Short Term Investments | 118.9 M | |
| Cash | 118.9 M | |
| Accounts Payable | 1.5 M | |
| Net Debt | -99.2 M | |
| 50 Day M A | 3.0398 | |
| Total Current Liabilities | 34.2 M | |
| Other Operating Expenses | 38.4 M | |
| Non Current Assets Total | 16.9 M | |
| Stock Based Compensation | 3.1 M |
Additional Tools for ProQR Stock Analysis
When running ProQR Therapeutics' price analysis, check to measure ProQR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProQR Therapeutics is operating at the current time. Most of ProQR Therapeutics' value examination focuses on studying past and present price action to predict the probability of ProQR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProQR Therapeutics' price. Additionally, you may evaluate how the addition of ProQR Therapeutics to your portfolios can decrease your overall portfolio volatility.